Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2007 Third Quarter Earnings
January 05 2007 - 8:55AM
PR Newswire (US)
NEW YORK, Jan. 5 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX), an international manufacturer and marketer of
pharmaceutical products, will release its Fiscal 2007 Third Quarter
financial results before the U.S. stock market opens on Tuesday,
January 16, 2007. Later that day, at 10:00 AM EDT, Forest will host
a conference call where Dr. Lawrence Olanoff, President and Chief
Operating Officer and Frank Perier, Senior Vice President and Chief
Financial Officer, will discuss the financial results and relevant
company and industry topics. The conference call will be webcast
live beginning at 10:00 AM EST on the Company's website
http://www.frx.com/ and also on the website
http://www.streetevents.com/. Please log on to either website at
least fifteen minutes prior to the conference call as it may be
necessary to download software to access the call. A replay of the
conference call will be available until January 31, 2007 at both
websites and also by dialing 1-800-642-1687 (US investors) or
+1-706-645-9291 (international investors), ID 5744720. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO) About
Forest Laboratories and Its Products Forest Laboratories
(http://www.frx.com/) is a US-based pharmaceutical company
dedicated to identifying, developing, and delivering products that
make a positive difference in peoples' lives. Forest Laboratories'
growing product line includes Lexapro(R) (escitalopram oxalate), an
SSRI indicated for adults for the initial and maintenance treatment
of major depressive disorder and for generalized anxiety disorder;
Namenda(R) (memantine HCl), an N-methyl- D-aspartate
(NMDA)-receptor antagonist indicated for the treatment of moderate
and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil),
an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan
medoxomil- hydrochlorothiazide), an angiotensin receptor blocker
and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated
in combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation. Except for the historical
information contained herein, this release contains
"forward-looking statements" within the meaning of the Private
Securities Reform Act of 1995. These statements involve a number of
risks and uncertainties, including the difficulty of predicting FDA
approvals, the acceptance and demand for new pharmaceutical
products, the impact of competitive products and pricing, the
timely development and launch of new products, and the risk factors
listed from time to time in the Company's SEC reports, including
the Company's Annual Report on Form 10-K for the fiscal year ended
March 31, 2006 and quarterly report filed on Form 10-Q for the
period ended September 30, 2006. *Benicar is a registered trademark
of Daiichi Sankyo, and Campral is a registered trademark of Merck
Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
http://photoarchive.ap.org/ DATASOURCE: FOREST LABORATORIES, INC.
CONTACT: Charles E. Triano, Vice President, Investor Relations, of
Forest Laboratories, Inc., +1-212-224-6714, or Web site:
http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024